Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15412814 | 0.94 | LMNA (0.52) | LMNAALDH1A1MAPK1L3MBTL1TDP1 | |
| SCHEMBL1290933 | 0.85 | CA12 (0.53) | LMNAALDH1A1MAPK1L3MBTL1POLB | |
| SCHEMBL394046 | 0.84 | LMNA (0.55) | LMNAALDH1A1MAPK1L3MBTL1TDP1 | |
| SCHEMBL18673 | 0.83 | ALDH1A1 (0.68) | LMNAALDH1A1MAPK1L3MBTL1TDP1 | |
| SCHEMBL3963428 | 0.83 | ALDH1A1 (0.68) | LMNAALDH1A1MAPK1L3MBTL1TDP1 | |
| SCHEMBL2926392 | 0.81 | ALDH1A1 (0.66) | LMNAALDH1A1MAPK1L3MBTL1TDP1 | |
| SCHEMBL118235 | 0.81 | ALDH1A1 (0.66) | LMNAALDH1A1MAPK1L3MBTL1TDP1 | |
| SCHEMBL28434793 | 0.81 | ALDH1A1 (0.66) | LMNAALDH1A1MAPK1L3MBTL1TDP1 | |
| SCHEMBL20624816 | 0.81 | ALDH1A1 (0.66) | LMNAALDH1A1MAPK1L3MBTL1TDP1 | |
| SCHEMBL28600680 | 0.81 | ALDH1A1 (0.66) | LMNAALDH1A1MAPK1L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0641439-B1 | REAGENTS AND METHODS FOR THE QUANTIFICATION OF IMIPRAMINE OR DESIPRAMINE IN BIOLOGICAL FLUIDS | ABBOTT LAB (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-0948489-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| EP-0876616-A2 | REAGENTS FOR MEASURING LEAD LEVELS VIA THE QUANTIFICATION OF PORPHOBILINOGEN | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998027069-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | disclosed |
| WO-1997024621-A2 | REAGENTS FOR MEASURING LEAD LEVELS VIA THE QUANTIFICATION OF PORPHOBILINOGEN | ABBOTT LABORATORIES (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5578500-A | Reagents and methods for the quantification of imipramine or desipramine in biological fluids | ABBOTT LABORATORIES (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0641439-A4 | REAGENTS AND METHODS FOR THE QUANTIFICATION OF IMIPRAMINE OR DESIPRAMINE IN BIOLOGICAL FLUIDS. | ABBOTT LAB (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0641439-A1 | REAGENTS AND METHODS FOR THE QUANTIFICATION OF IMIPRAMINE OR DESIPRAMINE IN BIOLOGICAL FLUIDS | ABBOTT LABORATORIES (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5340750-A | Reagents and methods for the quantification of imipramine or desipramine in biological fluids | ABBOTT LABORATORIES (US) | 1994-08-23 | — | — | US | disclosed |
| WO-1993003371-A1 | REAGENTS AND METHODS FOR THE QUANTIFICATION OF IMIPRAMINE OR DESIPRAMINE IN BIOLOGICAL FLUIDS | ABBOTT LABORATORIES (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | LMNA 1832/4885ALDH1A1 281/4885MAPK1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.